Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest Antivirals Stories

2013-11-02 08:21:25

WASHINGTON, Nov. 2, 2013 /PRNewswire/ -- Janssen R&D Ireland (Janssen) today announced the presentation of new data at The Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington, DC for the investigational protease inhibitor simeprevir (TMC435) in the treatment of genotype 1 chronic hepatitis C in treatment-naive and treatment-experienced adult patients with compensated liver disease. In analyses of the Phase 3 QUEST-1 and QUEST-2 studies...

2013-11-02 08:21:21

Sustained virologic response at post-treatment follow-up week 12 (SVR 12) seen in 100 per cent of patients to date in two of the three combination arms studied MONTREAL, Nov. 2, 2013 /CNW/ - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced interim results from an ongoing Phase II clinical trial evaluating the efficacy and safety of an all-oral regimen combining once-daily MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease...

2013-10-24 16:27:29

RARITAN, N.J., Oct. 24, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted unanimously (19 to 0) to recommend approval of the investigational protease inhibitor simeprevir (TMC435) administered once daily as a 150 mg capsule with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated...

2013-10-11 08:43:23

The addition of danoprevir to the current treatment regimen for patients with hepatitis C leads to high rates of remission, according to a new article in Gastroenterology, the official journal of the American Gastroenterological Association. The current standard of care for hepatitis C patients includes a combination of peginterferon and ribavirin. "Despite recent advances, the current hepatitis C treatment regimen is burdensome on the patient and prone to adverse events," said Patrick...

2013-10-08 08:29:11

TITUSVILLE, N.J., Oct. 8, 2013 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. (Janssen) announced today the acquisition of the investigational compound GSK2336805, an NS5a replication complex inhibitor in Phase 2 development for the treatment of chronic hepatitis C, from an affiliate of GlaxoSmithKline plc. Janssen has acquired all rights to develop and commercialize GSK2336805, including in combination with other drugs. Financial details of the agreement have not been disclosed. Janssen...

2013-10-08 08:28:26

Collaborative trial from Boehringer Ingelheim and Presidio Pharmaceuticals investigates triple-DAA regimen of faldaprevir, deleobuvir and PPI-668 RIDGEFIELD, Conn., Oct. 8, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that interim data from its Phase 2 hepatitis C (HCV) clinical collaboration (NCT01859962) with Presidio Pharmaceuticals have been accepted as a late breaker poster presentation at the 64th Annual Meeting of the American Association for the...

2013-10-07 23:18:33

Reportbuyer.com just published a new market research report: PharmaPoint: Hepatitis C Virus - United States Drug Forecast and Market Analysis. London (PRWEB) October 07, 2013 PharmaPoint: Hepatitis C Virus - United States Drug Forecast and Market Analysis Summary GlobalData has released its new Country report, “PharmaPoint: Hepatitis C Virus - United States Drug Forecast and Market Analysis”. Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute...

2013-10-03 16:23:17

Patients Need Access to Treatments, Including Ampligen(®) and Rituxan(®) GRAND RAPIDS, Mich., Oct. 3, 2013 /PRNewswire-USNewswire/ -- PANDORA Org and other patient organizations say a recent report from the U.S. Food and Drug Administration (FDA) shows the agency must take further action to open up opportunities for ME/CFS drug development. Titled "The Voice of the Patient," this report is a detailed summary of an April 25 FDA Patient-Focused Drug Development meeting, the first of its...

2013-10-01 12:30:34

RIDGEFIELD, Conn., Oct. 1, 2013 /PRNewswire/ -- New data from Boehringer Ingelheim's hepatitis C virus (HCV) clinical development program have been accepted for presentation at the 64(th) Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), also known as The Liver Meeting(®), taking place November 1-5 in Washington, D.C. Presentations will include data from several studies evaluating Boehringer Ingelheim's investigational compound, faldaprevir,...

2013-10-01 12:29:43

PHASE III TOP-LINE RESULTS EXPECTED BEGINNING LATER IN 2013 NORTH CHICAGO, Ill., Oct. 1, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that new data from its phase II hepatitis C clinical development program will be presented at The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington, D.C., November 1-5, 2013. In total, eight abstracts will be presented, four of which include additional analyses from the phase IIb AVIATOR...